Barclays PLC increased its holdings in Zai Lab Limited (NASDAQ:ZLAB – Free Report) by 33.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 72,547 shares of the company’s stock after buying an additional 18,147 shares during the quarter. Barclays PLC owned about 0.07% of Zai Lab worth $2,413,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of ZLAB. 1832 Asset Management L.P. acquired a new position in Zai Lab in the 4th quarter worth approximately $28,000. Quent Capital LLC acquired a new position in Zai Lab in the 1st quarter worth approximately $47,000. Tobam acquired a new stake in shares of Zai Lab during the 1st quarter worth approximately $122,000. Baader Bank Aktiengesellschaft acquired a new stake in shares of Zai Lab during the 4th quarter worth approximately $190,000. Finally, Ensign Peak Advisors Inc grew its stake in shares of Zai Lab by 7.3% during the 3rd quarter. Ensign Peak Advisors Inc now owns 5,850 shares of the company’s stock worth $200,000 after purchasing an additional 400 shares during the period. Institutional investors and hedge funds own 53.98% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on the stock. Citigroup dropped their price objective on shares of Zai Lab from $138.00 to $130.00 in a research note on Thursday, May 11th. Cantor Fitzgerald assumed coverage on shares of Zai Lab in a research note on Thursday, August 10th. They set an “overweight” rating and a $70.00 price objective on the stock. Finally, Bank of America dropped their price objective on shares of Zai Lab from $75.00 to $62.50 in a research note on Monday, June 12th.
Zai Lab Price Performance
Shares of NASDAQ:ZLAB opened at $24.52 on Wednesday. Zai Lab Limited has a 1 year low of $20.98 and a 1 year high of $53.95. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -6.00 and a beta of 1.09. The business’s 50 day moving average price is $27.89 and its 200-day moving average price is $32.84.
About Zai Lab
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors.